Sionna Therapeutics, Inc.
NASDAQ:SIONBiotechnology
+$0.68 today
- Market cap
- $134.35M
- Beta
- 1.29
- P/E (TTM)
- -19.7
- EPS (TTM)
- -$1.90
Volume 0.52M
Average 0.39M
SION Other Current Assets
Current assets not reported separately, such as prepaid expenses.
Sionna Therapeutics, Inc.NASDAQ: SION
Other Current Assets · Q1 FY2026 · quarter ended Mar 2026
Other current assets rises 19.8% from a year ago
Other current assets stood at $4.81M at the end of Q1 FY2026, up 19.8% from a year earlier and down 13.1% from the prior quarter. Over 3 fiscal years it compounded at +65.4% a year.
Context
- Other current assets amounted to 1.6% of total assets at the end of Q1 FY2026, up 0.5 pp from a year earlier.
- Other current assets increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether other current assets keeps rising in the next quarterly balance sheet after a +19.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Assets history
USD · from the balance sheet
- Latest · FY2025
- 5.54M USD
- Year-over-year change
- +60.3%
- 3-year CAGR
- +65.4%
| Period | Period end | Other Current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 5.54M | +60.3% |
| FY2024 | 2024-12-31 | 3.46M | +403.6% |
| FY2023 | 2023-12-31 | 686K | -43.9% |
| FY2022 | 2022-12-31 | 1.22M | — |
Other Current Assets vs competitors
How SION compares with its peers on the latest reported figures
- SION's Mar 2026 other current assets of $4.81M is the 7th highest of the 11 companies compared; the peer median is $8.4M.
- Its year-over-year change of +19.8% is the 6th highest of 10, against a peer median of +38.7%.
- Other current assets amounts to 1.6% of total assets for SION, versus a peer median of 1.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $28.69M | +243.3% | -65.9% | 7.7% | |
| Sep 2026 | $25M | -37.7% | +11.5% | 1.7% | |
| Mar 2026 | $23.58M | +60.9% | +38.4% | 4.7% | |
| Sep 2026 | $16.21M | +122.6% | — | 3.2% | |
| Mar 2026 | $9.4M | +55.8% | +0.9% | 2.4% | |
| Mar 2026 | $7.4M | +38.7% | +7.8% | 1.8% | |
| Mar 2026 | $4.81M | +19.8% | +65.4% | 1.6% | |
| Sep 2026 | $0 | -100.0% | — | 0.0% | |
| Jun 2026 | $0 | -100.0% | +52.2% | 0.0% | |
| Sep 2026 | $0 | -100.0% | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding SION) | $8.4M | +38.7% | +9.6% | 1.7% | |
Competitors are the stored peer set for SION. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Sionna Therapeutics, Inc.
NASDAQ:SION
Intrinsic Alpha fair value
Locked
Current Price
$2.97
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.